Ay et al developed a score for predicting the risk of venous thromboembolism (VTE) in cancer patients. This is based on the risk score of Khorana et al. The authors are from Medical University of Vienna.
Parameters:
(1) risk of thrombosis based on type of cancer
(2) prechemotherapy platelet count per µL
(3) hemoglobin in g/dL
(4) prechemotherapy white blood cell count per µL
(5) body mass index (BMI) in kg per square meter
(6) soluble P-selectin in ng/mL
(7) D-dimer in µg/mL
|
Parameter |
Finding |
Points |
|---|---|---|
|
type of cancer |
stomach, pancreas, brain (very high risk) |
2 |
|
|
lung, kidney, lymphoma, myeloma (high risk) |
1 |
|
|
other |
0 |
|
platelet count |
< 350,000 per µL |
0 |
|
|
>= 350,000 per µL |
1 |
|
hemoglobin |
>= 10 g/dL AND no therapy with erythropoietin-like drug |
0 |
|
|
< 10 g/dL OR therapy with erythropoietin-like drug |
1 |
|
white blood cell count |
<= 11,000 per µL |
0 |
|
|
> 11,000 per µL |
1 |
|
BMI |
< 35 kg per square meter |
0 |
|
|
>= 35 kg per square meter |
1 |
|
soluble P-selectin |
< 53.1 ng/mL (µg/L) |
0 |
|
|
>= 53.1 ng/mL |
1 |
|
D-dimer |
< 1.44 µg/mL (mg/L) |
0 |
|
|
>= 1.44 µg/mL |
1 |
where:
• The high risk cancer group in the score of Khorana et al included different tumors.
total score =
= SUM(points for all 7 parameters)
Interpretation:
• minimum score: 0
• maximum score: 8
• The higher the score the greater the likelihood of a venous thromboembolism occurring.
|
Score |
1 Year Risk of Venous Thromboembolism |
|
0 |
1.7% |
|
1 or 2 |
6% |
|
3 |
13% |
|
4 |
26% |
|
>= 5 |
35% |
Purpose: To identify a patient with cancer who is at increased risk for venous thromboembolism (VTE) based on the score of Ay et al.
Specialty: Hematology Oncology, Clinical Laboratory
Objective: risk factors, severity, prognosis, stage, complications
ICD-10: D62, O22, O87,
